A Phase 1 Study in Participants With Advanced Cancer
Completed
Eli Lilly and Company
Phase 1
The primary purpose of Parts A and B of this study is to evaluate the safety and toxicity of
prexasertib (an inhibitor of checkpoint kinase 1[chk 1]) in participants with advanced or
metastatic cancer (Part A), or squamous cell cancer of the head and neck or squamous cell
cancer of any tumor type (Part B). Part C of the study will evaluate prexasertib in three
different groups of participants; those with squamous cell cancer of the head and neck that
has recurred or spread to other parts of the body, those with squamous non-small cell lung
cancer that has recurred or spread, and those with squamous cell cancer of the anus that is
not curable by existing therapy.
A Study of Prexasertib (LY2606368) With Chemotherapy or Targeted Agents in Participants With Advanced Cancer
Completed
Eli Lilly and Company
Phase 1
The main purpose of this study is to investigate the safety of prexasertib in combination
with other anti-cancer drugs (cisplatin, cetuximab, pemetrexed, fluorouracil or LY3023414) in
participants with advanced cancer or cancer that has spread to another part of the body. The
study has multiple parts (A, B, C, D and E). Participants will only enroll in one part.
Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors.
Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data.
The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free.
We do not provide individual investment advice. This service is not registered with any financial regulatory agency. The information we publish is educational only and based on our opinions plus our models.
By using DrugPatentWatch you acknowledge that we do not provide personalized recommendations or advice.
thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user.
Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.
Alerts Available With Subscription
Alerts are available for users with active subscriptions.
